| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | TREVENA INC | 2,669,280 | 22,075,000 | 21.09% | ||
| 2 | T2 BIOSYSTEMS INC | 2,018,450 | 19,902,000 | 19.01% | ||
| 3 | GENOCEA BIOSCIENCES INC | 1,968,606 | 15,237,000 | 14.56% | ||
| 4 | OCULAR THERAPEUTIX INC | 1,230,009 | 11,882,000 | 11.35% | ||
| 5 | PULMATRIX INC | 3,607,996 | 10,571,000 | 10.10% | ||
| 6 | CERULEAN PHARMA INC | 3,287,529 | 8,909,000 | 8.51% | ||
| 7 | Life Technologies Corp | 1,827,992 | 7,202,000 | 6.88% | ||
| 8 | FATE THERAPEUTICS INC COM | 2,473,186 | 4,452,000 | 4.25% | ||
| 9 | BIND THERAPEUTICS INC | 2,018,253 | 4,440,000 | 4.24% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000950123-16-017102, filed 2016.05.13).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
